O. Pichelmayer

Bevacizumab is active in malignant effusion.

M. Raderer, C. Zielinski, B. Gruenberger, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Response of a nonmalignant pleural effusion to bevacizumab.

M. Raderer, C. Zielinski, O. Pichelmayer, 2005, The New England journal of medicine.

Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma

K. Harmankaya, G. Kramer, A. Haitel, 2010, BMC Cancer.

Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma.

A. Chott, H. Kaufmann, J. Drach, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

A. Chott, H. Kaufmann, J. Drach, 2006 .